A genetically altered variant of Cry9Ca from Bacillus thuringiensis shows high potency against the spruce budworm, Choristoneura fumiferana Clemens. Its activity, as measured by feeding inhibition in frass-failure assays, is estimated to be four to seven times greater than B. thuringiensis subsp. kurstaki HD-1, the strain currently used in commercial products to control this insect. Bioassays against budworm of mixtures of the modified Cry9Ca and two of the Cry1A endotoxin proteins produced by HD-1 show neither synergism nor antagonism. Experiments with brush border membrane vesicles from budworm midgut revealed that Cry9Ca and the Cry1A toxins share a common binding site and that bound Cry9Ca can be displaced from the membrane to some extent by the Cry1A toxins. However, it is uncertain whether the binding site is actually the receptor molecule or a membrane protein associated with pore formation.
Introduction
Forest protection against the spruce budworm, Choristoneura fumiferana Clemens, in North America relies almost entirely on commercial bioinsecticides based on the HD-1 strain of Bacillus thuringiensis subsp. kurstaki. There are four known cry genes in this strain that express N-endotoxins, all of which are active to varying degrees against spruce budworm. These are cry1Aa, cry1Ab, cry1Ac (formerly 4.5, 5.3 and 6.6 genes, respectively) [1] and cry2Aa (formerly cryBI, cryB1, cryIIA) [2^4] . A ¢fth gene, cry2Ab (formerly cryB2, cryIIB) [3, 4] , is also present, but may only be poorly expressed, if at all [4] . Cry1Aa and cry1Ab produce the most potent endotoxin proteins against spruce budworm [5] and are considered good candidates for the production of genetically modi¢ed trees as a defence against budworm attack. However, the risk of resistance development in the insect population from repeated exposure to B. thuringiensis, either through spray operations or expression in transgenic trees, has prompted a search for other genes that produce budworm active toxins. Ideally, these should not compete with HD-1 toxin proteins for the same midgut receptors.
In a previous study [6] , a genetically modi¢ed form of Cry9Ca [7] was found to be even more active against spruce budworm than the Cry1A toxins, as measured by feeding inhibition. In the engineered variant, the arginine residue at position 164 was replaced with alanine, eliminating a trypsin cleavage site and thereby increasing stability of the activated toxin [7] . In this study we further evaluated the potential of the genetically modi¢ed Cry9Ca as a candidate for commercial development against spruce budworm. We ¢rst compared the potency of the Cry9Ca toxin with HD-1 and investigated its interaction in vivo with Cry1Aa and Cry1Ab for possible synergism. Then we conducted in vitro experiments with brush border membrane vesicles (BBMVs) from budworm midgut to determine whether Cry9Ca and the Cry1A toxins bind independently to the membrane or interfere with each other.
Materials and methods

Toxin, antibody and BBMV preparation
Cry1A cloned gene products were produced in transformed Escherichia coli at the Biotechnology Research Institute, Montreal, Canada. The genetically altered Cry9-Ca was produced in E. coli at Plant Genetic Systems, Ghent, Belgium. The recombinants were obtained as starter cultures and grown at the Canadian Forest Service, Sault Ste. Marie. Culture conditions, cell harvesting and lysozyme treatment to recover protoxin inclusion bodies were as described previously [5] . Activation of Cry9Ca, Cry1Aa and Cry1Ab was according to Gringorten et al. [8] for the insect bioassays. Activation of toxins for the binding experiments was according to Pang [9] , following solubilization, acid precipitation, and resolubilization of the protoxins in 0.1 M bicarbonateN aOH bu¡er, pH 10.2 [10] . The precipitated protoxins were washed twice in sterile, deionized water prior to resolubilization.
All toxin preparations were dialyzed and clari¢ed by centrifugation before use: against 0.15 M CAPS^KOH bu¡er, pH 10.5, for the insect assays and 0.01 M phosphate-bu¡ered saline (PBS), pH 8.6, for the binding experiments. Total protein concentration was determined by the Bio-Rad microassay method, based on Bradford [11] , and referenced against either a Cry1A protein standard (insect assays) or bovine serum albumin (BSA; binding experiments). Toxin protein concentrations were determined by 0.1% sodium dodecyl sulfate^12% polyacrylamide gel electrophoresis (SDS^PAGE) and scanning densitometry of the gels.
BBMVs were prepared from spruce budworm midgut according to Wolfersberger et al. [12] and suspended in PBS, pH 8.6. BBMV protein concentration was determined by the Bio-Rad microassay method after removing an aliquot and solubilizing the BBMVs in PBS, pH 8.6, containing 1% Triton X-100.
Toxin interactions in vivo
Spruce budworm larvae were obtained from the insect rearing facility at the Canadian Forest Service in Sault Ste. Marie. Bioassays of spore-free, activated toxins against ¢rst-day, sixth-instars were performed by a droplet-feeding method [13] and toxicity calculated as the median and 95% e¡ective doses (ED 50 and ED 95 , respectively) that prevented insects from producing frass during 3 days post feed [14] . The 'frass-failure' response re£ects feeding inhibition. Observed ED 50 values for mixtures of the Cry1A and Cry9Ca toxins were compared with expected values, based on the relative proportion of each toxin in the mixtures and computation of the harmonic means of their individual values [15] .
Heterologous toxin binding to BBMVs
Dual toxin binding to BBMVs was investigated in a two-step procedure, in which saturation binding of one toxin to BBMVs was followed by incubation with a second toxin labeled with biotin. The method of Denolf et al. [16] was used to label the toxins with biotin. Toxin and BBMVs (2:1, w/w) were incubated together in PBS, pH 8.6, containing 0.02% BSA. Final concentrations of toxin and BBMV protein were 1.33 and 0.67 mg ml 31 , respectively. Following the incubation period, the suspension was centrifuged and the BBMVs washed six times in PBS, pH 8.6. The toxin^BBMVs were then incubated with a second, biotinylated toxin (1.33 mg ml 31 ), following which they were centrifuged and thoroughly washed as previously. BBMV pellets were analyzed for unlabeled toxin from the ¢rst binding by 0.1% SDS^10% PAGE and immunoblotting with antitoxin antisera [10] . Solubilization and boiling of BBMV-bound toxin in sample bu¡er in preparation for SDS^PAGE releases the toxin. BBMVbound biotinylated toxin was detected by the streptavidin^horseradish peroxidase (HRP) reaction for biotin [7] , using a 1000-fold dilution of the reagent in PBS, pH 8.6, containing 0.5% Tween 20. Displaced toxin in the supernatant was detected with antiserum.
Toxin binding sites on BBMVs
The binding pattern of Cry9Ca and the Cry1A toxins to BBMVs was analyzed by two-dimensional, crossed a⁄nity immunoelectrophoresis at pH 8.6 [9] . Toxin^BBMV pellets from the ¢rst binding were solubilized in bu¡er containing 0.5% Triton X-100. Bound toxin and free toxin (supernatant from the ¢rst binding) were placed in adjacent wells of a slab gel consisting of 1% agarose and 0.5% Triton X-100 and subjected to electrophoresis in the ¢rst dimension. Electrophoresis in the second dimension was performed across gels that had been prepared with antiserum (0.5% antiserum added to 9.5% agarose). After washing in PBS the gels were stained in Coomassie brilliant blue R-250.
Results
Potency of the modi¢ed Cry9Ca toxin against spruce budworm
ED 50 and ED 95 toxicity data for Cry9Ca against spruce budworm were reported in a previous study [6] and were noted as being signi¢cantly lower than the values for Cry1Ab. These and data from an earlier study [5] , in which Cry1Ab and HD-1 activity against spruce budworm were compared, provided an indirect means for deriving a preliminary estimate of the potency of the Cry9Ca toxin relative to HD-1. The results are summarized in Table 1 , and show that the Cry9Ca toxin may be as much as four to seven times more potent than HD-1 against sixth-instar spruce budworm.
Cry1A^Cry9Ca interactions in vivo
Bioassays against spruce budworm of the Cry1A toxins and Cry9Ca were performed alone and as mixtures to investigate possible interactions between them. Cry1AbĈ ry9Ca mixtures were tested in 1:1, 1:2 and 2:1 (w/w) combinations, based on toxin protein composition. Only one combination of Cry1Aa and Cry9Ca was tested (Cry1Aa/Cry9Ca, 2:1 w/w). The assays revealed no evidence of either synergism or antagonism between the two classes of toxins (Table 2 ). Observed and expected activities, as measured by ED 50 values, were not signi¢-cantly di¡erent.
Cry1A and Cry9Ca binding to BBMVs
The toxin/BBMV ratio of 2:1 (w/w) was su⁄cient to achieve saturation binding, as evident from the supernatants, which contained excess toxin at the end of the incubation period. The supernatants were subsequently used in the crossed a⁄nity immunoelectrophoresis (below). Immunodetection of toxins (unlabeled) from the ¢rst binding is illustrated in Fig. 1A and detection of biotinylated toxins from the second binding is illustrated in Fig. 2. Fig. 1A demonstrates that all three toxins were able to bind to BBMVs in the primary step and that subsequent incubation of the BBMVs with the heterologous toxin (Fig. 1A,  lanes 1, 2, 4 and 5) had no noticeable e¡ect. Anti-Cry1Aa and anti-Cry1Ab antibodies cross-react (not shown); neither one cross-reacts with anti-Cry9Ca (shown for Cry1Aa and anti-Cry9Ca in Fig. 1B) . Fig. 2 , however, points to a contrast between Cry9Ca and the Cry1A toxins in their ability to bind to BBMVs already bound with the heterologous toxin. Cry9Ca was unable to bind to Cry1A^BBMVs (Fig. 2, lanes 1 and 2) , whereas the Cry1A toxins were able to bind to Cry9CaT a Frass-failure assays of spore-free, activated toxins [14] . b Cry1Ab ED/HD-1 ED and Cry1Ab ED/Cry9Ca ED, from toxicity data in van Frankenhuyzen et al. [5, 6] , and based on toxin protein determinations (see Section 2). a Frass-failure assays of spore-free, activated toxins [14] ; 95% con¢dence interval in brackets. b Insects within each assay group were from the same cohort. BBMVs (Fig. 2, lanes 4 and 5) . There was no evidence of BBMV-bound Cry1A toxins being displaced into the supernatant by Cry9Ca (Fig. 3, lanes 1 and 2) , but it is evident that the Cry1A toxins were able to displace some of the bound Cry9Ca (Fig. 3, lanes 3 and 4) .
Binding sites for the Cry1A toxins and Cry9Ca on BBMVs
The results of the crossed a⁄nity immunoelectrophoresis are presented in Fig. 4 . Free toxin was placed in the lower well and BBMV-bound toxin was placed in the upper well of each gel. As noted in an earlier study [9] and con¢rmed here, free, activated toxins migrate toward the cathode (3), whereas BBMV-bound toxins migrate toward the anode (+). As expected, the free toxins gave rise to one peak in the slab gel impregnated with antitoxin antiserum (lower slab gel), following electrophoresis in the second dimension. Both BBMV-bound Cry1A toxins produced two peaks following immunoelectrophoresis in the second dimension (upper slab gel), whereas BBMV-bound Cry9Ca produced only one. Apparently, under present experimental conditions, the Cry1A toxins end up bound to two BBMV proteins and Cry9Ca ends up bound to just one.
Discussion
Using data from previous studies [5, 6] , we calculated that a genetically engineered form of Cry9Ca is signi¢-cantly more potent against the spruce budworm, C. fumiferana, than B. thuringiensis subsp. kurstaki HD-1, the strain used in commercial spray products to control this insect. The Cry9Ca toxin was estimated to be four times more potent than HD-1 at the ED 50 level and seven times more potent at the ED 95 level, as measured in frass-failure assays. Bioassays of mixtures of the Cry9Ca and Cry1A toxins revealed no evidence of either synergism or antagonism between the two classes of toxins at the levels and ratios tested.
Dual binding of Cry9Ca and the Cry1A toxins to budworm BBMVs was evaluated by incubating them sequentially with the BBMVs. The purpose was to determine whether saturation binding of one toxin (high toxin/ Fig. 3 . SDS^PAGE and immunodetection of displaced toxin in the supernatant. Rows 1 and 2 depict the toxin^BBMV binding procedure and are the same as in Fig. 1 . Row 3 is antitoxin antiserum tested against the supernatant for the presence of displaced toxin following the second binding (row 2). Cry9Ca failed to displace the Cry1A toxins (lanes 1 and 2) but the Cry1A toxins were able to displace Cry9Ca (lanes 4 and 5). Lane 5 is a negative control for displacement of bound Cry9Ca into the supernatant when BBMVs are incubated in bu¡er alone. Fig. 4 . Crossed a⁄nity immunoelectrophoresis (native agarose gels) of free, activated toxins (supernatant from the ¢rst binding ; lower wells) and toxins bound to spruce budworm BBMVs (upper wells). Following electrophoresis in the ¢rst dimension, the gel is cut, sandwiched between slab gels prepared with antiserum, and electrophoresed in the second direction. Free toxins migrate toward the cathode (3); BBMV-bound toxins migrate toward the anode (+).
BBMV ratio) and its insertion into the membrane would subsequently interfere with binding of the second toxin, and whether heterologous toxins were capable of displacing each other from the membrane. The presence of free toxin in the supernatant at the end of the 2 h incubation period (Fig. 4) is evidence that saturation binding conditions were achieved.
No e¡ect on binding of the ¢rst toxin to BBMVs by the second was apparent in the ¢rst experiment (Fig. 1A) . We have no clear explanation for the smear produced when Cry9Ca was used as the primary toxin (Fig. 1A, lanes 46 ), but one possibility may be incomplete release of Cry9-Ca from membrane proteins during solubilization in the sample bu¡er for the SDS^PAGE. The intense, discrete band (arrowhead) in Fig. 1A is evidently free toxin, whereas the smear may represent toxin bound to protein aggregates of various sizes. The inability of Cry9Ca to bind to BBMVs already bound with Cry1Aa or Cry1Ab toxins (Fig. 2, lanes 1  and 2) , under saturation binding conditions (2:1 Cry9-Ca/BBMV protein), is evidence of a common membrane binding site (or sites), one from which the Cry1A toxins could not be displaced (Fig. 3, lanes 1 and 2) . In marked contrast, however, Cry1Aa and Cry1Ab toxins were able to bind to BBMVs already bound with Cry9Ca (Fig. 2 , lanes 4 and 5) and displace some of the Cry9Ca (Fig. 3,  lanes 3 and 4) . The crossed a⁄nity immunoelectrophoresis (Fig. 4) suggests that, under saturation binding conditions, Cry1A toxins end up bound to two membrane sites on budworm BBMVs, whereas Cry9Ca ends up bound only to one. One of the Cry1A sites is evidently shared with Cry9Ca.
Whether the binding sites are receptors or other membrane proteins to which toxin molecules bind following insertion is uncertain. Furthermore, it cannot be discounted that the Cry9Ca found in the supernatant in the displacement experiment (Fig. 3, lanes 3 and 4) represents toxin that had already integrated into the membrane, rather than receptor-bound toxin, although this would run counter to evidence that toxin insertion is probably irreversible [17] . It appears certain, however, that it represents Cry9Ca initially bound to and then displaced from the BBMVs by the Cry1A toxins, rather than excess, free toxin. Evidence for this is the absence of a protein band in the control lane (Fig. 3, lane 5) , proof that excess Cry9Ca toxin was completely eliminated by the washing procedure. Nevertheless, the amount of displaced Cry9Ca appears to have been relatively small, as there is obviously much more that remained bound to the BBMVs (Fig. 1,  lanes 4 and 5) .
The present study leaves open the question as to why the genetically modi¢ed Cry9Ca toxin is much more active against spruce budworm than the individual Cry1A toxins or HD-1. Sequence comparisons using CLUSTAL W software [18] show only 34^35% amino acid identity between Cry9Ca and the two Cry1A toxins, and there are numerous possibilities worth exploring. Determination of speci¢c binding parameters, using a two-step kinetic analysis that di¡erentiates between the reversible (receptor binding) and irreversible (membrane insertion) components of binding [17] , would show whether or not Cry9Ca is a better pore former. It is also possible that the modi¢ed Cry9Ca can resist proteolytic degradation to a greater extent than the Cry1A toxins and is, therefore, more stable in the larval midgut. Finally, di¡erences in the extent to which Cry9Ca and the Cry1A toxins may be sequestered in the larval midgut by various mechanisms could also be a factor; these include binding by the peritrophic membrane [192 2] , precipitation [23, 24] , and binding to a soluble form of the midgut receptor [25] .
Although the modi¢ed Cry9Ca-activated toxin has been shown to be more e¡ective at causing feeding inhibition in spruce budworm than the Cry1A toxins, and by extension, more e¡ective than the HD-1 strain of B. thuringiensis subsp. kurstaki, feeding inhibition can be transient and a percentage of insects may recover and resume feeding. The potential commercial value of Cry9Ca, therefore, needs to be evaluated at the insecticidal level and in the presence of spores. This would show whether the di¡erence in activity between Cry9Ca and HD-1 extends to lethal doses in which septicemia is the predominant factor causing mortality.
Although no ¢nal conclusion is drawn at present regarding the binding sites, it is conceivable that one of the two peaks observed with both Cry1Aa and Cry1Ab in the crossed a⁄nity immunoelectrophoresis (Fig. 4) represents receptor-bound toxin, which could explain why preincubation of BBMVs with the Cry1A toxins prevented Cry9Ca from binding, at least at the toxin/BBMV ratio that was used. Proof of receptor sharing between Cry9Ca and the Cry1A toxins, however, will require heterologous competition assays in which toxins are exposed to BBMVs simultaneously, rather than sequentially. In considering the alternate or combined use of Cry9Ca and HD-1 (or one of its Cry1A toxins) in a control program for spruce budworm, as a strategy for reducing the risk of resistance development, the possibility of a common receptor would have to be taken into account. While a combination of Cry9Ca and a Cry1A toxin will have no negative interactive e¡ect on toxicity to spruce budworm, competition for a common midgut receptor might well nullify any advantage of such a strategy for managing resistance in this insect.
